What lies ahead for the proprotein convertases?

Annals of the New York Academy of Sciences

Volumn 1220, Issue 1, 2011, Pages 149-161

  Seidah, Nabil G ^a  

^a CLIN RESEARCH INSTITUTE OF MONTREAL   (Canada)

Author keywords

Clinical applications; In vivo functions; Physiological substrates; Proprotein convertases (PCs); Secretory pathway

Indexed keywords

FURIN; PROPROTEIN CONVERTASE 1; PROPROTEIN CONVERTASE 2; PROPROTEIN CONVERTASE 5; PROPROTEIN CONVERTASE 6; PROPROTEIN CONVERTASE 7; PROTEIN; PROTEIN PACE4; PROTEIN PCSK9; SERINE PROTEINASE; UNCLASSIFIED DRUG;

ARTICLE; ATHEROSCLEROSIS; CELL ADHESION; CELL DIFFERENTIATION; CELL FUNCTION; CELL GROWTH; CELL MIGRATION; DEGENERATIVE DISEASE; DIABETES MELLITUS; DISEASE ASSOCIATION; ENDOCRINE DISEASE; GENE EXPRESSION; HEALTH; HOMEOSTASIS; HUMAN; HYPERCHOLESTEROLEMIA; IN VIVO STUDY; METASTASIS; NONHUMAN; OBESITY; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; REGULATORY MECHANISM; REPRODUCTION;

EID: 79952466610     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2010.05883.x     Document Type: Article

References (100)

1. Puente, X.S., L.M. Sanchez, C.M. Overall, et al 2003. Human and mouse proteases: a comparative genomic approach. Nat. Rev. Genet. 4: 544-558.
2. Chretien, M., S., Benjannet, C. Lazure, et al 1983. Biosynthesis of hormonal and neural peptides. Trans. Am. Clin. Climatol. Assoc. 95: 19-25.
3. Docherty, K. & D.F. Steiner 1982. Post-translational proteolysis in polypeptide hormone biosynthesis. Annu. Rev. Physiol. 44: 625-638.
4. Seidah, N.G., G. Mayer, A. Zaid, et al 2008. The activation and physiological functions of the proprotein convertases. Int. J. Biochem. Cell Biol. 40: 1111-1125.
5. Seidah, N.G. & A. Prat 2007. The proprotein convertases are potential targets in the treatment of dyslipidemia. J. Mol. Med. 85: 685-696.
6. Seidah, N.G. 2009. PCSK9 as a therapeutic target of dyslipidemia. Expert. Opin. Ther. Targets. 13: 19-28.
7. Scamuffa, N., F. Calvo, M. Chretien, et al 2006. Proprotein convertases: lessons from knockouts. FASEB J. 20: 1954-1963.
8. Creemers, J.W. & A.M. Khatib 2008. Knock-out mouse models of proprotein convertases: unique functions or redundancy? Front Biosci. 13: 4960-4971.
9. Seidah, N.G., A.M. Khatib & A. Prat 2006. The proprotein convertases and their implication in sterol and/or lipid metabolism. Biol. Chem. 387: 871-877.
10. Hsi, K.L., N.G. Seidah, G. De Serres, et al 1982. Isolation and NH2-terminal sequence of a novel porcine anterior pituitary polypeptide. Homology to proinsulin, secretin and Rous sarcoma virus transforming protein TVFV60. FEBS Lett. 147: 261-266.
11. Mbikay, M., N.G. Seidah & M. Chretien 2001. Neuroendocrine secretory protein 7B2: structure, expression and functions. Biochem. J. 357: 329-342.
12. Malide, D., N.G. Seidah, M. Chretien, et al 1995. Electron microscopic immunocytochemical evidence for the involvement of the convertases PC1 and PC2 in the processing of proinsulin in pancreatic beta-cells. J. Histochem. Cytochem. 43: 11-19.
13. Yang, Y., Q.X. Hua, J. Liu, et al 2010. Solution structure of proinsulin: connecting domain flexibility and prohormone processing. J. Biol. Chem. 285: 7847-7851.
14. Zhu, X., L. Orci, R. Carroll, et al 2002. Severe block in processing of proinsulin to insulin accompanied by elevation of des-64, 65 proinsulin intermediates in islets of mice lacking prohormone convertase 1/3. Proc. Natl. Acad. Sci. USA 99: 10299-10304.
15. Furuta, M., A. Zhou, G. Webb, et al 2001. Severe defect in proglucagon processing in islet A-cells of prohormone convertase 2 null mice. J. Biol. Chem. 276: 27197-27202.
16. Jackson, R.S., J.W. Creemers, S. Ohagi 1997. Obesity and impaired prohormone processing associated with mutations in the human prohormone convertase 1 gene. Nat. Genet. 16: 303-306.
17. Jackson, R.S., J.W. Creemers, I.S. Farooqi, et al 2003. Small-intestinal dysfunction accompanies the complex endocrinopathy of human proprotein convertase 1 deficiency. J. Clin. Invest. 112: 1550-1560.
18. Farooqi, I.S., K. Volders, R. Stanhope, et al 2007. Hyperphagia and early-onset obesity due to a novel homozygous missense mutation in prohormone convertase 1/3. J. Clin. Endocrinol. Metab. 92: 3369-3373.
19. Furuta, M., H. Yano, A. Zhou, et al 1997. Defective prohormone processing and altered pancreatic islet morphology in mice lacking active SPC2. Proc. Natl. Acad. Sci. USA 94: 6646-6651.
20. Berman, Y., N. Mzhavia, A. Polonskaia, et al 2000. Defective prodynorphin processing in mice lacking prohormone convertase PC2. J. Neurochem. 75: 1763-1770.
21. Furuta, M., R. Carroll, S. Martin, et al. 1998. Incomplete processing of proinsulin to insulin accompanied by elevation of Des-31, 32 proinsulin intermediates in islets of mice lacking active PC2. J. Biol. Chem. 273: 3431-3437.
22. Zhang, X., H. Pan, B. Peng, et al 2010. Neuropeptidomic analysis establishes a major role for prohormone convertase-2 in neuropeptide biosynthesis. J. Neurochem. 112: 1168-1179.
23. Dey, A., C. Norrbom, X. Zhu, et al 2004. Furin and prohormone convertase 1/3 are major convertases in the processing of mouse pro-growth hormone-releasing hormone. Endocrinology 145: 1961-1971.
24. Posner, S.F., C.A. Vaslet, M. Jurofcik, et al 2004. Stepwise posttranslational processing of progrowth hormone-releasing hormone (proGHRH) polypeptide by furin and PC1. Endocrine 23: 199-213.
25. Zhu, X., A. Zhou, A. Dey, et al 2002. Disruption of PC1/3 expression in mice causes dwarfism and multiple neuroendocrine peptide processing defects. Proc. Natl. Acad. Sci. USA 99: 10293-10298.
26. Wardman, J.H., X. Zhang, S. Gagnon, et al 2010. Analysis of peptides in prohormone convertase 1/3 null mouse brain using quantitative peptidomics. J. Neurochem. 114: 215-225.
27. Benjannet, S., N. Rondeau, R. Day, et al 1991. PC1 and PC2 are proprotein convertases capable of cleaving proopiomelanocortin at distinct pairs of basic residues. Proc. Natl. Acad. Sci. USA 88: 3564-3568.
28. Seidah, N.G., R. Day, M. Marcinkiewicz, et al 1998. Precursor convertases: an evolutionary ancient, cell-specific, combinatorial mechanism yielding diverse bioactive peptides and proteins. Ann. N.Y. Acad. Sci. 839: 9-24.
29. Wetsel, W.C., Z. Liposits, N.G. Seidah, et al 1995. Expression of candidate pro-GnRH processing enzymes in rat hypothalamus and an immortalized hypothalamic neuronal cell line. Neuroendocrinology 62: 166-177.
30. Kotani, M., M. Detheux, A. Vandenbogaerde, et al 2001. The metastasis suppressor gene KiSS-1 encodes kisspeptins, the natural ligands of the orphan G protein-coupled receptor GPR54. J. Biol. Chem. 276: 34631-34636.
31. Tsutsui, K., E. Saigoh, K. Ukena, et al 2000. A novel avian hypothalamic peptide inhibiting gonadotropin release. Biochem. Biophys. Res. Commun. 275: 661-667.
32. Tsutsui, K., G.E. Bentley, L.J. Kriegsfeld, et al 2010. Discovery and evolutionary history of gonadotrophin-inhibitory hormone and kisspeptin: new key neuropeptides controlling reproduction. J. Neuroendocrinol. 22: 716-727.
33. Konoshita, T., J.M. Gasc, E. Villard, et al 1994. Co-expression of PC2 and proenkephalin in human tumoral adrenal medullary tissues. Biochimie 76: 241-244.
34. Croissandeau, G., F. Wahnon, K. Yashpal, et al 2006. Increased stress-induced analgesia in mice lacking the proneuropeptide convertase PC2. Neurosci. Lett. 406: 71-75.
35. Lloyd, D.J., S. Bohan & N. Gekakis 2006. Obesity, hyperphagia and increased metabolic efficiency in Pc1 mutant mice. Hum. Mol. Genet. 15: 1884-1893.
36. Benzinou, M., J.W. Creemers, H. Choquet, et al 2008. Common nonsynonymous variants in PCSK1 confer risk of obesity. Nat. Genet. 40: 943-945.
37. Corpeleijn, E., L. Petersen, C. Holst, et al 2010. Obesity-related polymorphisms and their associations with the ability to regulate fat oxidation in obese Europeans: the NUGENOB study. Obesity (Silver Spring) 18: 1369-1377.
38. Kojima, M., H. Hosoda, Y. Date, et al 1999. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 402: 656-660.
39. Zhang, J.V., P.G. Ren, O. Avsian-Kretchmer, et al 2005. Obestatin, a peptide encoded by the ghrelin gene, opposes Ghrelin's effects on food intake. Science 310: 996-999.
40. Yang, J., M.S. Brown, G. Liang, et al 2008. Identification of the acyltransferase that octanoylates ghrelin, an appetite-stimulating peptide hormone. Cell 132: 387-396.
41. Zhu, X., Y. Cao, K. Voogd, et al 2006. On the processing of proghrelin to ghrelin. J. Biol. Chem. 281: 38867-38870.
42. Gyamera-Acheampong, C., J. Tantibhedhyangkul, W. Weerachatyanukul, et al 2006. Sperm from mice genetically deficient for the PCSK4 proteinase exhibit accelerated capacitation, precocious acrosome reaction, reduced binding to egg zona pellucida, and impaired fertilizing ability. Biol. Reprod. 74: 666-673.
43. Tadros, H., M. Chretien & M. Mbikay 2001. The testicular germ-cell protease PC4 is also expressed in macrophage-like cells of the ovary. J. Reprod. Immunol. 49: 133-152.
44. Qiu, Q., A. Basak, M. Mbikay, et al 2005. Role of pro-IGF-II processing by proprotein convertase 4 in human placental development. Proc. Natl. Acad. Sci. USA 102: 11047-11052.
45. Mbikay, M., H. Tadros, N. Ishida, et al 1997. Impaired fertility in mice deficient for the testicular germ-cell protease PC4. Proc. Natl. Acad. Sci. USA 94: 6842-6846.
46. Li, M., M. Mbikay & A. Arimura 2000. Pituitary adenylate cyclase-activating polypeptide precursor is processed solely by prohormone convertase 4 in the gonads. Endocrinology 141: 3723-3730.
47. Basak, S., M. Chretien, M. Mbikay, et al 2004. In vitro elucidation of substrate specificity and bioassay of proprotein convertase 4 using intramolecularly quenched fluorogenic peptides. Biochem. J. 380: 505-514.
48. Majumdar, S., B.C. Mohanta, D.R. Chowdhury, et al 2010. Proprotein convertase inhibitory activities of flavonoids isolated from oroxylum indicum. Curr. Med. Chem. 17: 2049-2058.
49. Seidah, N.G. & M. Chretien 1999. Proprotein and prohormone convertases: a family of subtilases generating diverse bioactive polypeptides. Brain Res. 848: 45-62.
50. Thomas, G. 2002. Furin at the cutting edge: from protein traffic to embryogenesis and disease. Nat. Rev. Mol. Cell Biol. 3: 753-766.
51. Bresnahan, P.A., R. Leduc, L. Thomas, et al 1990. Human fur gene encodes a yeast KEX2-like endoprotease that cleaves pro-beta-NGF in vivo. J. Cell Biol. 111: 2851-2859.
52. Kalus, I., B. Schnegelsberg, N.G. Seidah, et al 2003. The proprotein convertase PC5A and a metalloprotease are involved in the proteolytic processing of the neural adhesion molecule L1. J. Biol. Chem. 278: 10381-10388.
53. Adams, R.H., M. Lohrum, A. Klostermann, et al 1997. The chemorepulsive activity of secreted semaphorins is regulated by furin-dependent proteolytic processing. EMBO J. 16: 6077-6086.
54. Parker, M.W., L.M. Hellman, P. Xu, et al 2010. Furin processing of semaphorin 3F determines its anti-angiogenic activity by regulating direct binding and competition for neuropilin. Biochemistry 49: 4068-4075.
55. Hallenberger, S., V. Bosch, H. Angliker, et al 1992. Inhibition of furin-mediated cleavage activation of HIV-1 glycoprotein gp160. Nature 360: 358-361.
56. Vollenweider, F., S. Benjannet, E. Decroly, et al 1996. Comparative cellular processing of the human immunodeficiency virus (HIV-1) envelope glycoprotein gp160 by the mammalian subtilisin/kexin-like convertases. Biochem. J. 314: 521-532.
57. Stieneke-Grober, A., M. Vey, H. Angliker, et al 1992. Influenza virus hemagglutinin with multibasic cleavage site is activated by furin, a subtilisin-like endoprotease. EMBO J. 11: 2407-2414.
58. Walker, J.A., S.S. Molloy, G. Thomas, et al 1994. Sequence specificity of furin, a proprotein-processing endoprotease, for the hemagglutinin of a virulent avian influenza virus. J. Virol. 68: 1213-1218.
59. Sun, X., L.V. Tse, A.D. Ferguson, et al 2010. Modifications to the hemagglutinin cleavage site control the virulence of a neurotropic H1N1 influenza virus. J. Virol. 84: 8683-8690.
60. Pasquato, A. & N.G. Seidah 2008. The H5N1 influenza variant Fujian-like hemagglutinin selected following vaccination exhibits a compromised furin cleavage: neurological consequences of highly pathogenic Fujian H5N1 strains. J. Mol. Neurosci. 35: 339-343.
61. Roebroek, A.J., L. Umans, I.G. Pauli, et al 1998. Failure of ventral closure and axial rotation in embryos lacking the proprotein convertase Furin. Development 125: 4863-4876.
62. Roebroek, A.J., N.A. Taylor, E. Louagie, et al 2004. Limited redundancy of the proprotein convertase furin in mouse liver. J. Biol. Chem. 279: 53442-53450.
63. Villeneuv, P., S. Feliciangeli, G. Croissandeau, et al 2002. Altered processing of the neurotensin/neuromedin N precursor in PC2 knock down mice: a biochemical and immunohistochemical study. J. Neurochem. 82: 783-793.
64. Siegfried, G., A. Basak, W. Prichett-Pejic, et al 2005. Regulation of the stepwise proteolytic cleavage and secretion of PDGF-B by the proprotein convertases. Oncogene 24: 6925-6935.
65. Siegfried, G., A. Basak, J.A. Cromlish, et al 2003. The secretory proprotein convertases furin, PC5, and PC7 activate VEGF-C to induce tumorigenesis. J. Clin. Invest. 111: 1723-1732.
66. Nelsen, S.M. & J.L. Christian 2009. Site-specific cleavage of BMP4 by furin, PC6, and PC7. J. Biol. Chem. 284: 27157-27166.
67. Seidah, N.G., S.J. Mowla, J. Hamelin, et al 1999. Mammalian subtilisin/kexin isozyme SKI-1: a widely expressed proprotein convertase with a unique cleavage specificity and cellular localization. Proc. Natl. Acad. Sci. USA 96: 1321-1326.
68. Pasquato, A., P. Pullikotil, M.C. Asselin, et al 2006. The proprotein convertase SKI-1/S1P: in vitro analysis of lassa virus glycoprotein-derived substrates and ex vivo validation of irreversible peptide inhibitors. J. Biol. Chem. 281: 23471-23481.
69. Espenshade, P.J., D. Cheng, J.L. Goldstein, et al 1999. Autocatalytic processing of site-1 protease removes propeptide and permits cleavage of sterol regulatory element-binding proteins. J. Biol. Chem. 274: 22795-22804.
70. Yang, J., J.L. Goldstein, R.E. Hammer, et al 2001. Decreased lipid synthesis in livers of mice with disrupted Site-1 protease gene. Proc. Natl. Acad. Sci. USA 98: 13607-13612.
71. Pullikotil, P., M. Vincent, S.T. Nichol, et al 2004. Development of protein-based inhibitors of the proprotein of convertase SKI-1/S1P: processing of SREBP-2, ATF6, and a viral glycoprotein. J. Biol. Chem. 279: 17338-17347.
72. Mouchantaf, R., H.L. Watt, T. Sulea, et al 2004. Prosomatostatin is proteolytically processed at the amino terminal segment by subtilase SKI-1. Regul. Pept. 120: 133-140.
73. Lenz, O., J. ter Meulen, H.D. Klenk, et al 2001. The lassa virus glycoprotein precursor GP-C is proteolytically processed by subtilase SKI-1/S1P. Proc. Natl. Acad. Sci. USA 98: 12701-12705.
74. Vincent, M.J., A.J. Sanchez, B.R. Erickson, et al 2003. Crimean-Congo hemorrhagic fever virus glycoprotein proteolytic processing by subtilase SKI-1. J. Virol. 77: 8640-8649.
75. Bryleva, E.Y., M.A. Rogers, C.C. Chang, et al 2010. ACAT1 gene ablation increases 24(S)-hydroxycholesterol content in the brain and ameliorates amyloid pathology in mice with AD. Proc. Natl. Acad. Sci. USA 107: 3081-3086.
76. Essalmani, R., J. Hamelin, J. Marcinkiewicz, et al 2006. Deletion of the gene encoding proprotein convertase 5/6 causes early embryonic lethality in the mouse. Mol. Cell. Biol. 26: 354-361.
77. Dong, W., M. Marcinkiewicz, D. Vieau, et al 1995. Distinct mRNA expression of the highly homologous convertases PC5 and PACE4 in the rat brain and pituitary. J. Neurosci. 15: 1778-1796.
78. Constam, D.B. & E.J. Robertson 2000. SPC4/PACE4 regulates a TGFbeta signaling network during axis formation. Genes Dev. 14: 1146-1155.
79. Essalmani, R., A. Zaid, J. Marcinkiewicz, et al 2008. In vivo functions of the proprotein convertase PC5/6 during mouse development: Gdf11 is a likely substrate. Proc. Natl. Acad. Sci. USA 105: 5750-5755.
80. Szumska, D., G. Pieles, R. Essalmani, et al 2008. VACTERL/caudal regression/Currarino syndrome-like malformations in mice with mutation in the proprotein convertase Pcsk5. Genes Dev. 22: 1465-1477.
81. Sun, X., R. Essalmani, N.G. Seidah, et al 2009. The proprotein convertase PC5/6 is protective against intestinal tumorigenesis: in vivo mouse model. Mol. Cancer 8: 73-81.
82. Xiao, Y., G. Chen, J. Richard, et al 2008. Cell-surface processing of extracellular human immunodeficiency virus type 1 Vpr by proprotein convertases. Virology 372: 384-397.
83. Malfait, A.M., E.C. Arner, R.H. Song, et al 2008. Proprotein convertase activation of aggrecanases in cartilage in situ. Arch. Biochem. Biophys. 478: 43-51.
84. Tortorella, M.D., E.C. Arner, R. Hills, et al 2005. ADAMTS-4 (aggrecanase-1): N-terminal activation mechanisms. Arch. Biochem. Biophys. 444: 34-44.
85. Seidah, N.G., S. Benjannet, L. Wickham, et al 2003. The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation. Proc. Natl. Acad. Sci. USA 100: 928-933.
86. Abifadel, M., M. Varret, J.P. Rabes, et al 2003. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat. Genet. 34: 154-156.
87. Cohen, J., A. Pertsemlidis, I.K. Kotowski, et al 2005. Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9. Nat. Genet. 37: 161-165.
88. Nassoury, N., D.A. Blasiole, O.A. Tebon, et al 2007. The cellular trafficking of the secretory proprotein convertase PCSK9 and its dependence on the LDLR. Traffic 8: 718-732.
89. Rashid, S., D.E. Curtis, R. Garuti, et al 2005. Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9. Proc. Natl. Acad. Sci. USA 102: 5374-5379.
90. Zaid, A., A. Roubtsova, R. Essalmani, et al 2008. Proprotein convertase subtilisin/kexin type 9 (PCSK9): hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration. Hepatology 48: 646-654.
91. Zhao, Z., Y. Tuakli-Wosornu, T.A. Lagace, et al 2006. Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote. Am. J. Hum. Genet. 79: 514-523.
92. Cohen, J.C., E. Boerwinkle, T.H. Mosley, Jr., et al 2006. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N. Engl. J. Med. 354: 1264-1272.
93. Lakoski, S.G., T.A. Lagace, J.C. Cohen, et al 2009. Plasma levels of PCSK9 in a large multiethnic population. J. Clin. Endocrinol. Metab. 94: 2537-2543.
94. Mayer, G., S. Poirier & N.G. Seidah 2008. Annexin A2 is a C-terminal PCSK9-binding protein that regulates endogenous low density lipoprotein receptor levels. J. Biol. Chem. 283: 31791-31801.
95. Dubuc, G., M. Tremblay, G. Pare, et al 2010. A new method for measurement of total plasma PCSK9: clinical applications. J. Lipid Res. 51: 140-149.
96. Chan, J.C., D.E. Piper, Q. Cao, et al 2009. A proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates. Proc. Natl. Acad. Sci. USA 106: 9820-9825.
97. Graham, M.J., K.M. Lemonidis, C.P. Whipple, et al 2007. Antisense inhibition of proprotein convertase subtilisin/kexin type 9 reduces serum LDL in hyperlipidemic mice. J. Lipid Res. 48: 763-767.
98. Frank-Kamenetsky, M., A. Grefhorst, N.N. Anderson, et al 2008. Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates. Proc. Natl. Acad. Sci. USA 105: 11915-11920.
99. Gupta, N., N. Fisker, M.C. Asselin, et al 2010. A locked nucleic acid antisense oligonucleotide (LNA) silences PCSK9 and enhances LDLR expression in vitro and in vivo. PLoS ONE 5: e10682.
100. Horton, J.D., J.C. Cohen & H.H. Hobbs 2009. PCSK9: a convertase that coordinates LDL catabolism. J. Lipid Res. 50: S172-S177.